There are many advantages of partnering with PGXIS. For example, we bring an expert eye to the development planning using existing pharmacogenetic knowledge. In addition, our siRNA technology allows application of this technology to new areas where pharmacogenetic knowledge is currently limited.
We are particularly keen to identify compounds in late pre-clinical development, as incorporating PGx into the clinical planning from an early stage will maximise the beneficial impact of the technology and give rise to the greatest probability of success in the clinic.
As pharmacogenomics has been shown to reduce attrition in drug development, we are keen to identify compounds that have failed in clinical studies so that we can apply our expertise to re-activate these programmes.
We want to make an impact in oncology and neurology, and many other therapeutic areas where modern genetics has established key genes important for the disease aetiology, such as Alzheimer's disease, Parkinson's disease, type II diabetes and obesity. We also want to be involved in diseases with childhood onset.
Please contact us so we can meet to discuss your compounds and your ideas.